Jenburkt Pharmaceuticals Ltd — Board Meeting, 20-05-2025: Board Meeting

Jenburkt Pharmaceuticals Limited has announced a board meeting to approve the financial results for the quarter and half-year ended March 31, 2025. The board approved a 180% dividend per equity share (face value Rs. 10) for FY 2024-25. The company scheduled its 40th Annual General Meeting via virtual means. Shri Ashish Uttam Bhuta was re-appointed as Chairman and Managing Director for a five-year term starting April 1, 2026, with remuneration approved for three years. The auditors issued an unmodified opinion on the standalone financial statements. The company reported a solid profit after tax of Rs. 3206.06 lakh for FY 2024-25, up from Rs. 2597.73 lakh the previous year, with revenue increasing to Rs. 15169.15 lakh from Rs. 14196.65 lakh. Internal controls and financial reporting systems were deemed effective.